414 related articles for article (PubMed ID: 7697935)
1. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients.
Deetjen A; Heidland A; Pangerl A; Meyer-Sabellek W; Schaefer RM
Clin Nephrol; 1995 Jan; 43(1):47-52. PubMed ID: 7697935
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension.
Miki S; Masumura H; Kaifu Y; Yuasa S
J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S62-8. PubMed ID: 1721982
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of carvedilol in severe hypertension.
Ogihara T; Yoshinaga K; Kamahara Y; Ikeda M; Goto Y; Arakawa K; Iimura I; Ishii M; Kokubu T; Takeda T
J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S69-72. PubMed ID: 1721983
[TBL] [Abstract][Full Text] [Related]
4. A new molecule with vasodilating and beta-adrenoceptor blocking properties.
Abshagen U
J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S23-32. PubMed ID: 2454364
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with dual-acting drugs in hypertension.
Rahn KH
Clin Investig; 1992; 70 Suppl 1():S39-42. PubMed ID: 1350483
[TBL] [Abstract][Full Text] [Related]
6. Carvedilol: a third-generation β-blocker should be a first-choice β-blocker.
DiNicolantonio JJ; Hackam DG
Expert Rev Cardiovasc Ther; 2012 Jan; 10(1):13-25. PubMed ID: 22149523
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients.
Masumura H; Miki S; Kaifu Y; Kitajima W; Abe Y
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S102-7. PubMed ID: 1378134
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of carvedilol in older and younger patients.
Morgan T; Anderson A; Cripps J; Adam W
J Hum Hypertens; 1990 Dec; 4(6):709-15. PubMed ID: 2096213
[TBL] [Abstract][Full Text] [Related]
9. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study.
McPhillips JJ; Schwemer GT; Scott DI; Zinny M; Patterson D
Drugs; 1988; 36 Suppl 6():82-91. PubMed ID: 2908306
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive profile of carvedilol.
Meyer-Sabellek W; Agrawal B
Clin Investig; 1992; 70 Suppl 1():S43-52. PubMed ID: 1350484
[TBL] [Abstract][Full Text] [Related]
11. Effect of long-term carvedilol therapy on renal function in essential hypertension.
Tomita K; Marumo F
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S97-101. PubMed ID: 1378158
[TBL] [Abstract][Full Text] [Related]
12. Influence of salt intake on the antihypertensive effect of carvedilol.
Ruilope LM; Lahera V
J Hypertens Suppl; 1993 Jun; 11(4):S17-9. PubMed ID: 8104238
[TBL] [Abstract][Full Text] [Related]
13. Use of carvedilol in hypertension: an update.
Leonetti G; Egan CG
Vasc Health Risk Manag; 2012; 8():307-22. PubMed ID: 22661898
[TBL] [Abstract][Full Text] [Related]
14. A multicenter comparison of carvedilol with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension.
Langdon CG; Baxter GA; Young PH
J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S51-6. PubMed ID: 1721980
[TBL] [Abstract][Full Text] [Related]
15. Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey.
Mori Y; Nishikawa Y; Iizuka T; Zenimura N; Matsumoto T; Hiramatsu K; Komiya M
Drugs R D; 2011; 11(2):171-90. PubMed ID: 21679007
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with carvedilol.
Moser M
J Hum Hypertens; 1993 Feb; 7 Suppl 1():S16-20. PubMed ID: 8098064
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan.
Kohno M; Takeda T; Ishii M; Saruta T; Mizuno Y; Yoshimura M; Kubo S; Fukiyama K; Fujishima M
Drugs; 1988; 36 Suppl 6():129-35. PubMed ID: 2908299
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency.
Gehr TW; Tenero DM; Boyle DA; Qian Y; Sica DA; Shusterman NH
Eur J Clin Pharmacol; 1999 Jun; 55(4):269-77. PubMed ID: 10424319
[TBL] [Abstract][Full Text] [Related]
19. Response rate with respect to the blood pressure-lowering effect of the vasodilating and beta-blocking agent carvedilol.
Rittinghausen R
Drugs; 1988; 36 Suppl 6():92-101. PubMed ID: 2908307
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
